Overview

• Rocket Pharmaceuticals reports Q3 net loss of $50.3 mln, reduced from prior year

• R&D and G&A expenses decreased due to disciplined resource allocation

• Company to resume pivotal Phase 2 trial for Danon disease in 1H 2026

Outlook

• Rocket expects cash resources to fund operations into Q2 2027

• Company anticipates dosing additional patients for RP-A501 in H1 2026

• KRESLADI™ PDUFA date set for March 28, 2026

Result Drivers

• AAV CARDIOVASCULAR FOCUS - Co maintained strategic focus on AAV cardiovascular gene therapy portfolio, resuming pivotal Phase 2 trial for Danon disease

• EXPENSE REDUCTION - Decrease in R&D and G&A expenses attributed to disciplined resource allocation after organizational realignment

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $8.00, about 58.5% above its November 5 closing price of $3.32

Press Release: ID:nBw8h2fYLa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)